Can we accurately predict cost effectiveness without access to overall survival data? The case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in England

Lee, D., Amadi, A., Sabater, J. et al. (9 more authors) (2019) Can we accurately predict cost effectiveness without access to overall survival data? The case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in England. PharmacoEconomics - Open, 3 (1). pp. 43-54. ISSN 2509-4262

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 The Authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Dates:
  • Published (online): 22 May 2018
  • Published: March 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 26 Feb 2020 15:10
Last Modified: 26 Feb 2020 19:33
Status: Published
Publisher: Springer Nature
Refereed: Yes
Identification Number: https://doi.org/10.1007/s41669-018-0080-5
Related URLs:

Share / Export

Statistics